Breaking News
Investing Pro 0
Cyber Monday Extended SALE: Up to 60% OFF InvestingPro+ CLAIM OFFER

After-Hours Movers: Novavax Sinks Over 30%, GoodRx and Lemonade Climb

Stock Markets Aug 08, 2022 22:18
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
BBBY
+1.69%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
DDD
+0.49%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
NVAX
-1.96%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
TREX
-2.29%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
CRMD
+3.73%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
CARG
0.00%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

GoodRx Holdings, Inc. (GDRX) +34%; Revenue for the quarter came in at $191.8 million versus the consensus estimate of $185.36 million.

Lemonade (LMND) +13%; reported Q2 EPS of ($1.10), $0.23 better than the analyst estimate of ($1.33). Revenue for the quarter came in at $50 million versus the consensus estimate of $47.56 million.GUIDANCE: Lemonade sees Q3 2022 revenue of $63-65 million, versus the consensus of $56.98 million. Lemonade sees FY2022 revenue of $236-239 million, versus the consensus of $214.67 million.

Bed Bath & Beyond (NASDAQ:BBBY) +9%; extends earlier gain after meme stocks bid higher.

CorMedix (CRMD) -58%; today announced updates related to the FDA review of the DefenCath New Drug Application (NDA) as well as other manufacturing and commercial updates. A second Complete Response Letter (CRL) was received from the FDA stating that the DefenCath NDA cannot be approved until deficiencies recently conveyed to the contract manufacturing organization (CMO) and the supplier of the active pharmaceutical ingredient (API) heparin during inspections are resolved to the satisfaction of FDA.

Novavax (NASDAQ:NVAX) -32%; Novavax (NVAX) reported Q2 EPS of ($6.53), $12.03 worse than the analyst estimate of $5.50. Revenue for the quarter came in at $186 billion versus the consensus estimate of $1.02 billion. GUIDANCE: Novavax sees FY2022 revenue of $2-2.3 billion, versus the consensus of $4.27 billion.

TaskUs, Inc. (TASK) -16%; reported Q2 EPS of $0.38, $0.05 better than the analyst estimate of $0.33. Revenue for the quarter came in at $246.5 million versus the consensus estimate of $242.11 million. GUIDANCE: TaskUs, Inc. sees Q3 2022 revenue of $224-226 million, versus the consensus of $244 million. TaskUs, Inc. sees FY2022 revenue of $930-950 million, versus the consensus of $992 million.

CarGurus (NASDAQ:CARG) -15%; reported Q2 EPS of $0.32, $0.01 better than the analyst estimate of $0.31. Revenue for the quarter came in at $511.2 million versus the consensus estimate of $507.32 million. GUIDANCE: CarGurus sees Q3 EPS of $0.25-$0.28, versus the consensus of $0.33. CarGurus sees Q3 revenue of $460-490 million, versus the consensus of $554.6 million.

3D Systems (NYSE:DDD) -13% ; reported Q2 EPS of ($0.07), $0.07 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $140 million versus the consensus estimate of $146.8 million. GUIDANCE: 3D Systems sees 2022 revenue of $530-570 million, versus the consensus of $598 million.

Allbirds, Inc. (BIRD) -13%; reported Q2 EPS of ($0.12), $0.04 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $78.2 million versus the consensus estimate of $77.8 million. GUIDANCE: Allbirds, Inc. sees FY2022 revenue of $305-315 million, versus the consensus of $339.6 million.

Trex (TREX) -12%; reported Q2 EPS of $0.79, $0.12 better than the analyst estimate of $0.67. Revenue for the quarter came in at $386 million versus the consensus estimate of $381.1 million. GUIDANCE: Trex sees Q3 2022 revenue of $185-195 million, versus the consensus of $354.82 million. Trex sees FY2022 revenue of $1.09-1.11 billion, versus the consensus of $1.38 billion.

After-Hours Movers: Novavax Sinks Over 30%, GoodRx and Lemonade Climb
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email